Lexicon Pharmaceuticals to Participate in December Investor Conferences THE WOODLANDS, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company…
Lexicon Appoints Ivan H. Cheung to Board of Directors THE WOODLANDS, Texas, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Ivan…
Lexicon Pharmaceuticals: Exklusive Partnerschaft mit Viatris bietet gemäß der Experten gigantisches Potenzial! Lexicon Pharmaceuticals Inc. (LXRX) ist ein Biotech mit Fokus auf Behandlungsmethoden von schwerwiegenden chronischen Krankheiten. Das Unternehmen nutzt dabei die…
Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists THE WOODLANDS, Texas, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that three…
Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024 THE WOODLANDS, Texas, May 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation…
Lexicon Pharmaceuticals secures $250 million in private financing By Investing.com Lexicon Pharmaceuticals secures $250 million in private financing…
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities THE WOODLANDS, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced it…
MSCLF: AAK1 Disclosed as Drug Target for DMD Program… By David Bautz, PhD OTC:MSCLF READ THE FULL MSCLF RESEARCH REPORT Business Update AAK1 Disclosed as Drug Target for DMD Program On November 14, 2023,…
Lexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference THE WOODLANDS, Texas, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation…
Lexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference THE WOODLANDS, Texas, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation…
Lexicon Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call and Webcast on November 8, 2023 THE WOODLANDS, Texas, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its third…
Lexicon Pharmaceuticals to Participate in the H.C. Wainwright & Co. 25th Annual Global Investment Conference THE WOODLANDS, Texas, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation…
Insiderhandel: Chief Executive Officer kauft Aktien von Lexicon Pharmaceuticals im Wert von 21.600$ Coats, Lonnel - Vorstand - Tag der Transaktion: 2023-06-29...…
Insiderhandel: VP, Human Resources kauft Aktien von Lexicon Pharmaceuticals im Wert von 24.300$ Mcdermott, Wendy - Vorstand - Tag der Transaktion: 2023-06-23...…
Insiderhandel: Chief Executive Officer kauft Aktien von Lexicon Pharmaceuticals im Wert von 21.792$ Coats, Lonnel - Vorstand - Tag der Transaktion: 2023-06-26...…
Insiderhandel: Chief Executive Officer kauft Aktien von Lexicon Pharmaceuticals im Wert von 24.950$ Coats, Lonnel - Vorstand - Tag der Transaktion: 2023-06-23...…